Business
Physiomics Expands Technical Team
Physiomics Expands Technical Team.
About this update from Physiomics Plc
[{"type":"text","content":"\n \nRNS Number : 2860T Physiomics PLC 02 July 2018 \n\nPhysiomics plc\n(\"Physiomics\") or (\"the Company\")\n \nPhysiomics expands technical team\n \nPhysiomics is pleased to announce that Dr Claire Villette has joined its technical team as a Biosimulation scientist.\n \nClaire is a biomedical computational scientist with 6 years' experience in multiscale modelling of biological tissue growth. She completed her PhD in Computational Biomechanics at Imperial College London where she was awarded an EPSRC Doctoral Prize fellowship to investigate new digital design optimisation techniques for tissue engineering scaffolds using machine learning algorithms. Claire has also completed a secondment at an Imperial College spin-out where she developed a commercial software application for tailored tissue engineering.\n \nJim Millen commented \"As Physiomics continues to expand its client base we need talented young scientists to help us deliver the high-quality work our clients have become used to. I'm confident that Claire will be a great addition to the team\".\n \nFor further information please contact:\n \nPhysiomics Plc\nDr Jim Millen\n+44 (0)1865 784980\n \nWH Ireland Limited (nomad)\nKaty Mitchell/James Sinclair-Ford\n+44 (0) 161 832 2174\n \nHybridan LLP (broker)\nClaire Louise Noyce\n+44 (0) 203 764 2341 \n \n \nAbout Physiomics plc\n \nPhysiomics plc (AIM: PYC) is a solutions provider to the R&D-based pharmaceutical and biotechnology industry with a focus on oncology. The Company's Virtual Tumour technology uses computer modelling to predict the effects of cancer drugs and treatments to improve the success rate of drug discovery and development projects while reducing time and cost. The predictive capability of Virtual Tumour has been confirmed by over 60 projects, involving over 25 targets and 60 drugs.\n \nBased in Oxford, UK, the Company works with clients worldwide to support their pre-clinical and clinical oncology development programs. Its team of scientists and computer modelling experts provide bespoke solutions encompassing data, analytics and insight. \n \nPhysiomics' senior management has academic and commercial expertise, including over 90 years collectively of working in oncology and/or computational biology and over 100 publications in...